# Quality Assurance Report

---

# Identity

| Field | Value |
|-------|-------|
| QA Report ID | QA-PP-0140 |
| Population Package | PP-0140 |
| Version | 1.0.0 |
| Review Status | PASS |

---

# Layer 1 — Content QA

| Criterion | Result |
|-----------|--------|
| Single educational question | PASS |
| Scope respected | PASS |
| Complete coverage | PASS |
| Internal consistency | PASS |
| Logical organization | PASS |
| Knowledge blocks complete | PASS |
| No overlap with adjacent Population Packages | PASS |

---

# Layer 2 — Clinical QA

| Criterion | Result |
|-----------|--------|
| Scientifically accurate | PASS |
| Consistent with ACMG | PASS |
| Consistent with AMP | PASS |
| Consistent with ClinGen SVI | PASS |
| Consistent with CAP | PASS |
| Consistent with NCI | PASS |
| Consistent with NCCN | PASS |
| Consistent with ASCO | PASS |
| Consistent with ACS | PASS |
| Consistent with ESMO | PASS |
| Appropriate explanation of BP4 | PASS |
| Appropriate explanation of computational evidence | PASS |
| Appropriate explanation of multiple independent computational methods | PASS |
| Appropriate explanation of supporting benign evidence | PASS |
| Appropriate distinction between supporting benign evidence and final benign classification | PASS |
| Appropriate clarification that BP4 provides supporting—not definitive—evidence | PASS |
| No unsupported clinical claim | PASS |
| No unsafe medical advice | PASS |

---

# Layer 3 — Educational QA

| Criterion | Result |
|-----------|--------|
| Plain language | PASS |
| Appropriate for patients | PASS |
| Learning objectives satisfied | PASS |
| Common misconceptions addressed | PASS |
| Appropriate explanation that computational predictions assist—but do not replace—expert interpretation | PASS |
| Appropriate clarification that BP4 is interpreted together with other evidence categories | PASS |
| Encourages discussion with healthcare professionals | PASS |

---

# Layer 4 — Governance QA

| Criterion | Result |
|-----------|--------|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Evidence Package completed | PASS |
| Evidence traceability complete | PASS |
| Scope maintained | PASS |
| Knowledge Graph complete | PASS |
| Versioning complete | PASS |
| Repository compliant | PASS |

---

# Clinical Safety Review

| Item | Result |
|------|--------|
| No unsafe medical advice | PASS |
| No unsupported interpretation guidance | PASS |
| Appropriate clarification that BP4 is not equivalent to a benign diagnosis | PASS |
| Appropriate clarification that computational evidence contributes supporting rather than definitive benign evidence | PASS |
| Appropriate explanation that expert interpretation remains essential | PASS |
| No disease-specific treatment recommendations | PASS |

---

# Educational Boundary Review

The Population Package successfully remains within the predefined educational boundary.

Included:

- definition of BP4;
- computational evidence;
- multiple independent computational prediction methods;
- Supporting Benign Evidence;
- patient implications.

Excluded:

- individual computational prediction tools;
- REVEL;
- CADD;
- PolyPhen-2;
- SIFT;
- SpliceAI;
- machine learning methodology;
- Bayesian framework;
- ACMG evidence combination rules;
- laboratory workflow;
- treatment recommendations.

The **Atomic Knowledge Principle** has been fully preserved.

---

# Final Quality Decision

## PASS

PP-0140 satisfies the locked **Gold Population Package Specification v1.0**.

Approved as the official Population Package for:

> **PP-0140 — BP4 (Multiple Lines of Computational Evidence Suggest No Impact on Gene or Gene Product)**

---

# Reviewer Notes

This Population Package introduces **BP4**, one of the individual **Supporting Benign Evidence** criteria within the ACMG/AMP framework. It explains, in patient-friendly language, that **multiple independent computational prediction methods consistently suggesting that a variant is unlikely to affect gene or protein function may contribute supporting benign evidence**, while emphasizing that **BP4 alone never establishes benign classification**. Individual computational prediction tools, machine-learning methodologies, prediction score interpretation, ClinGen implementation guidance, Bayesian implementation, and ACMG evidence-combination rules are intentionally deferred to dedicated Population Packages, maintaining strict adherence to the **Atomic Knowledge Principle**.